Abstract
Exposure of ZR-75-1 human breast cancer cells for 48 h to human recombinant interferon alpha (IFN alpha) resulted in increased expression of oestrogen receptors as measured in a whole cell binding assay. This effect was inversely proportional to dose being significant following treatment with 10-100 IU IFN ml-1 and was only observed at a low initial cell plating density. The extent of the increase in oestrogen receptor levels ranged from 1.2- to 7.2-fold following treatment with 10 IU IFN ml-1. No increase in progesterone receptor expression was observed under the same experimental conditions. Concentrations of IFN which increased oestrogen receptor levels had no effect on cell proliferation. IFN (500 IU ml-1) inhibited cell proliferation and the combination of this treatment with tamoxifen (2 microM) had a greater anti-proliferative effect than either drug alone although there was no evidence of synergism. However, a 5-day pretreatment of cells with IFN (10 IU ml-1) markedly sensitised them to the growth-inhibiting effect of a subsequent 6-day exposure to tamoxifen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
van den Berg, H., Leahey, W., Lynch, M. et al. Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen. Br J Cancer 55, 255–257 (1987). https://doi.org/10.1038/bjc.1987.49
Issue Date:
DOI: https://doi.org/10.1038/bjc.1987.49
This article is cited by
-
Antitumour actions of interferons: implications for cancer therapy
Nature Reviews Cancer (2016)
-
Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: Results of a multicentric phase II trial
Breast Cancer Research and Treatment (1995)
-
Immunological Therapy of Breast Cancer
Clinical Immunotherapeutics (1994)